[HTML][HTML] Adverse events in apheresis: an update of the WAA registry data
MM Henriksson, E Newman, V Witt, K Derfler… - … and apheresis science, 2016 - Elsevier
Apheresis with different procedures and devices are used for a variety of indications that
may have different adverse events (AEs). The aim of this study was to clarify the extent and …
may have different adverse events (AEs). The aim of this study was to clarify the extent and …
Guidelines on the use of therapeutic apheresis in clinical practice—evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is
charged with reviewing, updating and categorizating indications for therapeutic apheresis …
charged with reviewing, updating and categorizating indications for therapeutic apheresis …
[HTML][HTML] Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future
XL Chen, JW Mao, YD Wang - World Journal of Gastrointestinal …, 2020 - ncbi.nlm.nih.gov
The etiology and pathogenesis of inflammatory bowel disease (IBD), including ulcerative
colitis and Crohn's disease, are not fully understood so far. Therefore, IBD still remains …
colitis and Crohn's disease, are not fully understood so far. Therefore, IBD still remains …
Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study
R Sacco, A Romano, A Mazzoni… - Journal of Crohn's …, 2013 - academic.oup.com
Background: Despite the mounting importance of granulocytapheresis (GCAP) for
inflammatory bowel disease (IBD) treatment, its effectiveness in steroid-dependent (SD) and …
inflammatory bowel disease (IBD) treatment, its effectiveness in steroid-dependent (SD) and …
A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis
T Yamamoto, T Iida, K Ikeya, M Kato… - Clinical and …, 2018 - journals.lww.com
Objectives: Adsorptive granulomonocytapheresis (GMA) with the Adacolumn has been
introduced as a nonpharmacologic treatment for ulcerative colitis (UC). However, a subset of …
introduced as a nonpharmacologic treatment for ulcerative colitis (UC). However, a subset of …
Peripheral neutrophil functions and cell signalling in Crohns disease
R Somasundaram, VJAA Nuij, CJ van der Woude… - PLoS …, 2013 - journals.plos.org
The role of the innate immunity in the pathogenesis of Crohn's disease (CD), an
inflammatory bowel disease, is a subject of increasing interest. Neutrophils (PMN) are key …
inflammatory bowel disease, is a subject of increasing interest. Neutrophils (PMN) are key …
Concomitant pharmacologic medications influence the clinical outcomes of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis: a …
N Ueno, Y Sugiyama, Y Kobayashi… - Journal of Clinical …, 2023 - Wiley Online Library
Background Granulocyte and monocyte adsorptive apheresis (GMA) with Adacolumn has
been used as a remission induction therapy for patients with active ulcerative colitis (UC) …
been used as a remission induction therapy for patients with active ulcerative colitis (UC) …
Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a …
N Ueno, Y Sugiyama, Y Kobayashi, Y Murakami… - BMC …, 2021 - Springer
Background Granulocyte and monocyte adsorptive apheresis (GMA) is widely used as a
remission induction therapy for active ulcerative colitis (UC) patients. However, there are no …
remission induction therapy for active ulcerative colitis (UC) patients. However, there are no …
Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing …
T Shimoyama, T Yamamoto, S Umegae… - BMC …, 2018 - Springer
Background Calprotectin is a stable neutrophil protein, which can be measured in faecal
samples. The faecal level of calprotectin increases during disease activity in ulcerative colitis …
samples. The faecal level of calprotectin increases during disease activity in ulcerative colitis …
Adsorptive granulocyte and monocyte apheresis in the treatment of ulcerative colitis: the first multicenter study in China
YM Lai, WY Yao, Y He, X Jiang, YB Gu… - Gut and …, 2016 - pmc.ncbi.nlm.nih.gov
Background/Aims Patients with active ulcerative colitis (UC) have elevated levels of
activated myeloid-derived leukocytes as a source of inflammatory cytokines. The selective …
activated myeloid-derived leukocytes as a source of inflammatory cytokines. The selective …